yahoo_financeOriginal article
Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models
Data ReadoutpositiveAramcholEnzalutamidePositive
AI Analysis
Summary
Galmed announced preclinical results showing Aramchol demonstrated 3-4 fold increase in cell death compared to Enzalutamide alone in prostate cancer models. The company presented first-time results from its prostate oncology studies.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Aramchol demonstrated 3-4 fold increase in cell death compared to Enzalutamide alone in prostate cancer models
Importance:5/10
Sentiment:
0.70
prostate canceroncologypreclinical datacell deathcombination therapy
Read the original article
Published by yahoo_finance on August 17, 2026 1:15 PM